Partnership for Part D Access
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us

Newsroom​ 

Bloomberg Law: Leave Medicare Drug Coverage Alone, Patient Advocates Say

11/29/2018

0 Comments

 
Picture
An article for Bloomberg Law touches on a new report from the Partnership for Part D Access which demonstrates that Medicare Part D plans are successfully using tools to push patients toward less expensive drugs under the six protected classes policy. The article notes that the study, conducted by Avalere Health, shows drug plans are tools such as requiring copays for brand drugs in the protected classes to control patient costs and promote access to cost-effective treatments. The piece amplifies the concerns of patient advocates in response to proposed changes from the Administration. “Making changes to the policy because of cost is reckless,” said Chad Worz of the American Society of Consultant Pharmacists.  “It’s not something you play with to get a cheaper drug.”

0 Comments



Leave a Reply.

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    September 2022
    November 2021
    March 2021
    February 2021
    January 2021
    November 2020
    January 2020
    July 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    April 2018
    March 2018
    September 2017
    May 2017
    April 2017
    November 2016
    July 2016

    Categories

    All

    RSS Feed

Learn more

About Us
Patient Communities
​Issues
​Background

What's New?

​Newsroom
Resources
​

Contact

Contact Us
© COPYRIGHT 2018. ALL RIGHTS RESERVED.